Latest Articles

Publication Date
Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study.

Venous thromboembolism is a serious safety concern in women using combined oral contraceptives; ethinyl estradiol (EE) is widely used as an estrogen. Estetrol (E4) is a native estrogen with selective …

Published: Oct. 13, 2024, 4:35 p.m.
P2X3 and P2X2/3 Receptors Inhibition Produces a Consistent Analgesic Efficacy: A Systematic Review and Meta-Analysis of Preclinical Studies.

P2X3 and P2X2/3 receptors are promising therapeutic targets for pain treatment and selective inhibitors are under evaluation in ongoing clinical trials. Here we aim to consolidate and quantitatively evaluate the …

Published: Oct. 9, 2024, midnight
PAK5-mediated PKM2 phosphorylation is critical for anaerobic glycolysis in endometriosis.

P21-activated kinase 5 (PAK5) belongs to the PAK-II subfamily, which is an important regulator of cell survival, adhesion, and motility. However, the functions of PAK5 in endometriosis remain unclear. Here, …

Published: Sept. 27, 2024, midnight
Zearalenone promotes endometrial cancer cell migration and invasion via activation of estrogen receptor-mediated Rho/ROCK/PMLC signaling pathway.

Zearalenone (ZEA), has emerged as a potential endocrine-disrupting chemical (EDC). Previous results show ZEA effects on endometrial stromal cell apoptosis, migration, and growth of endometriosis. Despite the reported presence of …

Published: Sept. 19, 2024, midnight
Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.

SWI/SNF (SWItch/Sucrose Non-Fermentable) is the most frequently mutated chromatin-remodelling complex in human malignancy, with over 20% of tumours having a mutation in a SWI/SNF complex member. Mutations in specific SWI/SNF …

Published: Sept. 3, 2024, midnight
Rubraca sheds positive light for PARP inhibitors in endometrial cancer - Clinical Trials Arena

Rubraca sheds positive light for PARP inhibitors in endometrial cancer Clinical Trials Arena

Published: April 2, 2024, 7 a.m.
Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.

Melatonin, a potent antioxidant and free radical scavenger, has been demonstrated to be effective in gynecological conditions and female reproductive cancers. This review consolidates the accumulating evidence on melatonin's multifaceted …

Published: March 11, 2024, midnight
The effects of Rituximab on experimental endometriosis model in rats.

Endometriosis is a common, chronic benign gynecologic disease and distresses women in their reproductive age. Yet the pathogenesis of endometriosis is not clear, multifactorial mechanisms have been characterized for the …

Published: Feb. 7, 2023, midnight
Insights Into the Regulation of Gynecological Inflammation-Mediated Malignancy by Metalloproteinases.

Gynecological illness accounts for around 4.5% of the global disease burden, which is higher than other key global health concerns such as malaria (1.04%), TB (1.9%), ischemic heart disease (2.2%), …

Published: Nov. 29, 2021, midnight
Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma.

Although endometrioid carcinoma (EC) and endometrioid ovarian carcinoma (EnOC) display similar pathological features, their molecular characteristics remain to be determined. Somatic mutation data from 2777 EC, 423 EnOC, and 57 …

Published: Nov. 27, 2021, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!